Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aorn.2011.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and Management of Medical Comorbidities in Patients With HR+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Literature Review and Recommendations From Experts in Spain Opinion.
Clin Breast Cancer
December 2024
Navarra University Hospital, Pamplona, Navarra, Spain. Electronic address:
Approximately one-third of patients with breast cancer have comorbidities at the time of their diagnosis. Recommendations for managing metastatic breast cancer are usually based on the results of clinical trials, which often limit patients with comorbidities. However, comorbidities greatly influence the quality of life, patient survival rate and treatment choice, particularly in older patients.
View Article and Find Full Text PDFChallenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases.
Cancer Treat Rev
January 2025
Reina Sofía University Hospital, Córdoba, Spain.
The global incidence of metastatic melanoma with BRAF mutations, characterized by aggressive behavior and poor prognosis, is rising. Recent treatment advances, including immune checkpoint inhibitors (ICI) and targeted therapies (TT) such as BRAF and MEK inhibitors, have significantly enhanced patient outcomes. Although guidelines recommend sequencing strategies, real-world implementation can be influenced by clinical scenarios.
View Article and Find Full Text PDFPrognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.
Int J Gynecol Cancer
January 2025
The NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Macarthur Cancer Therapy Centre, Sydney, NSW, Australia; Western Sydney University, Department of Medicine, Sydney, NSW, Australia. Electronic address:
Objective: We evaluated the accuracy of oncologists' estimates of expected survival time in recurrent ovarian cancer.
Methods: Oncologists estimated expected survival time at baseline for each patient, who were then followed up for survival time. We hypothesized that oncologists' estimates of expected survival time would be independently significant predictors of survival, unbiased (approximately equal proportions [50%] living longer versus shorter than their expected survival time), or imprecise (<30% within 0.
Key takeaways: Gynecologic cancer breakthroughs at ESMO Congress 2024.
Int J Gynecol Cancer
January 2025
Hospital 9 de Julho-Dasa Oncologia, São Paulo, Brazil.
The "Key Takeaways: Gynecological cancer breakthroughs at ESMO Congress 2024" aims to include the most original and potentially practice-changing research in gynecologic oncology presented during the Annual Congress of the European Society of Medical Oncology, held in Barcelona, Spain, September 13 to 17, 2024. The scientific program encompassed a wide range of topics across various fields within oncology, and we selected 13 studies presented during the conference considered highly significant in the field of gynecologic oncology.
View Article and Find Full Text PDFSecond-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.
JHEP Rep
February 2025
Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
Background & Aims: Atezolizumab/bevacizumab (A/B) is now a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but the optimal second-line regimen is not known. We evaluated real-world treatment patterns and outcomes to investigate factors associated with post-progression survival (PPS).
Methods: In this multicenter, international, retrospective study, we examined clinical characteristics and outcomes of patients with advanced HCC who progressed on first-line A/B.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!